PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
News|Articles|September 13, 2013
Catalent Appoints First President of Asia Pacific Group
Author(s)Pharmaceutical Technology Editors
Catalent appoints David Heyens as President of Asia Pacific facility.
Advertisement
Catalent
has named David Heyens in the new role of president of Catalent Asia Pacific. Reporting directly to Catalent’s president and CEO, John Chiminski, Heyens was hired to drive Catalent’s growth in the region following the company’s recent expansion into China, and build on Catalent’s regional operations in Japan, Australia, and Singapore.
Replacing Heyens as the president of Catalent Softgel Technologies will be Aris Gennadios, PhD. Also reporting to Chiminski, Gennadios will have full strategic responsibility for the soft gel development, delivery, and supply business with 10 global manufacturing facilities that deliver pharmaceutical, generic, and consumer health soft gel products to markets worldwide.
Source:
Catalent
Advertisement
Related to this article
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Advertisement
Advertisement